Form 4: Olema Pharmaceuticals Director Acquires 23,000 Stock Options
SEC Form 4 Filing
Director J. Scott Garland acquired 23,000 stock options in Olema Pharmaceuticals on June 14, 2024, according to a Form 4 filing.
Summary
- On June 14, 2024, J. Scott Garland, a director of Olema Pharmaceuticals, acquired 23,000 stock options.
- The exercise price of these options is $12.36.
- The options vest in 12 equal monthly installments starting from June 14, 2024, contingent upon continuous service.
- Full vesting occurs at the next annual meeting if not fully vested by then, also subject to continuous service.
- The options expire on June 14, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option acquisition, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders, allowing investors to monitor their investment decisions.
Stakeholder Impact
- The acquisition of stock options by a director may signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of earliest transaction: acquisition of 23,000 stock options. |
| 06/14/2024 | Vesting start date for the stock options. |
| 06/18/2024 | Date of signature on the Form 4 filing. |
| 06/14/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.